We are live on
!
Find out more
F
Fithian Portfolio holdings
AUM
$47.9M
This Fund
S&P 500
This Quarter
Est. Return
+8.96%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$21M
AUM Growth
–
Cap. Flow
+$20.9M
Cap. Flow
% of AUM
99.53%
Top 10 Holdings %
Top 10 Hldgs %
95.5%
Holding
14
New
14
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Idexx Laboratories
IDXX
|
+$3.99M |
| 2 |
Bio-Techne
TECH
|
+$3.41M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$2.54M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$2.07M |
| 5 |
Zoetis
ZTS
|
+$2.05M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.05% |
| 2 | Communication Services | 19.69% |
| 3 | Financials | 13.99% |
| 4 | Technology | 6.26% |
| 5 | Consumer Discretionary | 1.01% |
Similar funds
CCM
6C
SAM
CM
UPC
ZCM
ACM
CFA
Fithian's Q4 2022 Portfolio in Review
Q4 2022 is the first quarter with a 13F filing on record for Fithian, which disclosed 14 positions worth $21M. Its ten largest holdings account for 96% of the portfolio.
Its largest position is Idexx Laboratories: 10,290 shares worth $4.2M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, followed by Communication Services and Financials.
- Fithian's largest Q4 2022 buy was Idexx Laboratories: 10,290 shares worth $4.2M.
- Fithian's ten largest holdings make up 96% of its $21M portfolio in Q4 2022.
- Fithian disclosed 14 positions in Q4 2022, its first 13F filing on record.
Based on Fithian's 13F filing for Q4 2022, filed 15 Feb 2023.